vs

Side-by-side financial comparison of Sweetgreen, Inc. (SG) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Sweetgreen, Inc. is the larger business by last-quarter revenue ($161.5M vs $151.7M, roughly 1.1× Tarsus Pharmaceuticals, Inc.). Sweetgreen, Inc. runs the higher net margin — 77.9% vs -5.5%, a 83.4% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -2.9%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -6.5%).

Sweetgreen is an American fast casual restaurant chain that serves salads. It was founded in November 2006 by Nicolas Jammet, Nathaniel Ru, and Jonathan Neman. In August 2007, they opened their first store in Washington, D.C., three months after they graduated from the McDonough School of Business at Georgetown University.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

SG vs TARS — Head-to-Head

Bigger by revenue
SG
SG
1.1× larger
SG
$161.5M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+131.3% gap
TARS
128.4%
-2.9%
SG
Higher net margin
SG
SG
83.4% more per $
SG
77.9%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-6.5%
SG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
SG
SG
TARS
TARS
Revenue
$161.5M
$151.7M
Net Profit
$125.8M
$-8.4M
Gross Margin
Operating Margin
68.7%
-5.3%
Net Margin
77.9%
-5.5%
Revenue YoY
-2.9%
128.4%
Net Profit YoY
602.5%
63.8%
EPS (diluted)
$1.05
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SG
SG
TARS
TARS
Q1 26
$161.5M
Q4 25
$155.2M
$151.7M
Q3 25
$172.4M
$118.7M
Q2 25
$185.6M
$102.7M
Q1 25
$166.3M
$78.3M
Q4 24
$160.9M
$66.4M
Q3 24
$173.4M
$48.1M
Q2 24
$184.6M
$40.8M
Net Profit
SG
SG
TARS
TARS
Q1 26
$125.8M
Q4 25
$-49.7M
$-8.4M
Q3 25
$-36.1M
$-12.6M
Q2 25
$-23.2M
$-20.3M
Q1 25
$-25.0M
$-25.1M
Q4 24
$-29.0M
$-23.1M
Q3 24
$-20.8M
$-23.4M
Q2 24
$-14.5M
$-33.3M
Operating Margin
SG
SG
TARS
TARS
Q1 26
68.7%
Q4 25
-31.0%
-5.3%
Q3 25
-21.0%
-12.2%
Q2 25
-14.2%
-21.6%
Q1 25
-17.2%
-33.5%
Q4 24
-19.5%
-36.8%
Q3 24
-12.2%
-52.3%
Q2 24
-8.8%
-81.6%
Net Margin
SG
SG
TARS
TARS
Q1 26
77.9%
Q4 25
-32.0%
-5.5%
Q3 25
-21.0%
-10.6%
Q2 25
-12.5%
-19.8%
Q1 25
-15.1%
-32.1%
Q4 24
-18.0%
-34.8%
Q3 24
-12.0%
-48.7%
Q2 24
-7.8%
-81.6%
EPS (diluted)
SG
SG
TARS
TARS
Q1 26
$1.05
Q4 25
$-0.42
$-0.17
Q3 25
$-0.31
$-0.30
Q2 25
$-0.20
$-0.48
Q1 25
$-0.21
$-0.64
Q4 24
$-0.25
$-0.57
Q3 24
$-0.18
$-0.61
Q2 24
$-0.13
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SG
SG
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$156.8M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$488.9M
$343.4M
Total Assets
$912.7M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SG
SG
TARS
TARS
Q1 26
$156.8M
Q4 25
$89.2M
$417.3M
Q3 25
$130.0M
$401.8M
Q2 25
$168.5M
$381.1M
Q1 25
$183.9M
$407.9M
Q4 24
$214.8M
$291.4M
Q3 24
$234.6M
$317.0M
Q2 24
$244.6M
$323.6M
Total Debt
SG
SG
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
SG
SG
TARS
TARS
Q1 26
$488.9M
Q4 25
$356.1M
$343.4M
Q3 25
$393.3M
$335.1M
Q2 25
$423.3M
$332.6M
Q1 25
$432.8M
$342.5M
Q4 24
$446.1M
$224.5M
Q3 24
$463.3M
$237.5M
Q2 24
$470.1M
$252.2M
Total Assets
SG
SG
TARS
TARS
Q1 26
$912.7M
Q4 25
$788.1M
$562.2M
Q3 25
$824.8M
$534.6M
Q2 25
$831.9M
$495.0M
Q1 25
$834.3M
$500.8M
Q4 24
$856.8M
$377.0M
Q3 24
$858.0M
$376.3M
Q2 24
$859.2M
$376.8M
Debt / Equity
SG
SG
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SG
SG
TARS
TARS
Operating Cash FlowLast quarter
$-17.2M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
-0.14×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SG
SG
TARS
TARS
Q1 26
$-17.2M
Q4 25
$-8.7M
$19.3M
Q3 25
$-1.4M
$18.3M
Q2 25
$10.5M
$-29.4M
Q1 25
$-13.1M
$-20.7M
Q4 24
$6.1M
$-22.2M
Q3 24
$14.7M
$-8.7M
Q2 24
$19.1M
$-14.4M
Free Cash Flow
SG
SG
TARS
TARS
Q1 26
Q4 25
$-39.0M
$13.0M
Q3 25
$-37.2M
$16.3M
Q2 25
$-13.1M
$-30.4M
Q1 25
$-29.9M
$-21.2M
Q4 24
$-20.6M
$-22.3M
Q3 24
$-10.3M
$-8.9M
Q2 24
$-156.0K
$-15.4M
FCF Margin
SG
SG
TARS
TARS
Q1 26
Q4 25
-25.1%
8.6%
Q3 25
-21.6%
13.8%
Q2 25
-7.1%
-29.6%
Q1 25
-18.0%
-27.1%
Q4 24
-12.8%
-33.5%
Q3 24
-6.0%
-18.6%
Q2 24
-0.1%
-37.8%
Capex Intensity
SG
SG
TARS
TARS
Q1 26
Q4 25
19.6%
4.2%
Q3 25
20.8%
1.6%
Q2 25
12.7%
1.0%
Q1 25
10.1%
0.8%
Q4 24
16.6%
0.1%
Q3 24
14.4%
0.6%
Q2 24
10.4%
2.5%
Cash Conversion
SG
SG
TARS
TARS
Q1 26
-0.14×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons